BG Medicine Given New $4.00 Price Target at Robert W. Baird (BGMD)
Analysts at Robert W. Baird decreased their price target on shares of BG Medicine (NASDAQ: BGMD) from $5.00 to $4.00 in a research report issued to clients and investors on Thursday. The firm currently has an “outperform” rating on the stock.
Shares of BG Medicine (NASDAQ: BGMD) traded down 4.30% during mid-day trading on Thursday, hitting $1.78. BG Medicine has a one year low of $1.00 and a one year high of $7.50. The stock’s 50-day moving average is currently $1.96. The company’s market cap is $36.5 million.
BG Medicine, Inc. (BG Medicine) is a life sciences company focused on the discovery, development and commercialization of cardiovascular diagnostics to addresses unmet medical needs.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.